7-氟-1-甲基-3-甲基磺酰基喹啉-4-酮 | 76568-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氟-1-甲基-3-甲基磺酰基喹啉-4-酮
• 英文名称: Flosequinan sulfone
• 英文别名: 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone；7-fluoro-1-methyl-3-methylsulfonyl-4-quinolone；flosequinoxan；flosequinan sulphone；7-fluoro-1-methyl-3-methylsulfonylquinolin-4-one
• CAS: 76568-68-8
• 化学式: C₁₁H₁₀FNO₃S
• 分子量: 255.27
• InChiKey: ZUMVHPMHCIKNFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  5

ADMET

代谢

Flosequinan sulfone是人类已知的flosequinan的代谢物。

Flosequinan sulfone is a known human metabolite of flosequinan.

来源:NORMAN Suspect List Exchange

反应信息

• 作为产物：
  描述：

  氟司喹南 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以64%的产率得到7-氟-1-甲基-3-甲基磺酰基喹啉-4-酮
  参考文献：
  名称：

  Birch, Alan M.; Davies, Roy V.; Maclean, Lachlan, Journal of the Chemical Society. Perkin transactions I, 1994, # 4, p. 387 - 392

  摘要：

  DOI：

文献信息

• Treatment of cardiovascular disease with quinolinone enantiomers
  申请人：R.T. Alamo Ventures I, L.L.C.

  公开号：US20020143031A1

  公开（公告）日：2002-10-03

  The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.

  本发明涉及用于治疗心血管疾病的组合物和方法。在一个优选实施例中，本发明考虑在未同时接受硝酸盐或硝酸酯治疗的受试者中使用氟斯奎南的对映体（以及含有氟斯奎南的配方）。
• Process for the preparation of 1-methyl-3-methylthio-4-quinolone and the
  申请人：The Boots Company PLC

  公开号：US05011931A1

  公开（公告）日：1991-04-30

  A process to prepare compounds of formula I ##STR1## in which n=0, 1 or 2 comprising the cyclisation of compounds of formula II ##STR2## in which n=0, 1 or 2. The cyclisation may be effected in the presence of an organic or inorganic base or thermally at a temperature in the range 40.degree.-160.degree. C. Compounds of formula II and certain analogues thereof are disclosed as cardiovascular agents.

  一种制备公式I化合物的过程，其中n = 0、1或2，包括公式II化合物的环化反应，其中n = 0、1或2。环化反应可以在有机或无机碱的存在下或在40℃-160℃范围内进行热反应。公式II化合物及其某些类似物被披露为心血管药物。
• Chemical process
  申请人：The Boots Co. PLC

  公开号：US05079264A1

  公开（公告）日：1992-01-07

  A process to prepare compounds of formula I ##STR1## in which n=0, 1 or 2 comprising the cyclization of compounds of formula II ##STR2## in which n=0, 1 or 2. The cyclization may be effected in the presence of an organic or inorganic base or thermally at a temperature in the range 40.degree.-160.degree. C. Compounds of formula II and certain analogues thereof are disclosed as cardiovascular agents.

  一种制备化合物I的过程，其中n = 0、1或2，包括将化合物II环化的步骤，其中n = 0、1或2。环化可以在有机或无机碱的存在下或在40℃-160℃的温度范围内热化学反应。公开了化合物II及其某些类似物作为心血管药剂。
• Methods for the treatment of central nervous system disorders in certain patient groups
  申请人：R.T. Alamo Ventures I, LLC

  公开号：US20030130311A1

  公开（公告）日：2003-07-10

  Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的中枢神经系统疾病的方法和组合物，包括但不限于抽动症。本发明的方法包括在没有心脏疾病和/或未接受有机硝酸酯的症状表现为中枢神经系统障碍的患者中利用含有喹啉酮（及其衍生物）的制药组合物。
• TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS
  申请人：R.T. Alamo Ventures I, L.L.C,

  公开号：US20020143030A1

  公开（公告）日：2002-10-03

  Methods for treating specific patient groups for gastroparesis are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives) in patients with symptoms of gastroparesis who are otherwise free of cardiac disease and/or who have not been given organic nitrates.

  本发明提供了用于治疗特定患者群体的胃排空障碍的方法。本发明的方法包括在没有心脏疾病和/或未被给予有机硝酸酯的胃排空障碍症状患者中利用含有喹啉酮（和衍生物）的药物组合物。